A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild-to-moderate Alzheimer's disease
Latest Information Update: 31 Jul 2023
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 08 Nov 2007 New trial record.